Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wartner is an over-the-counter medical device product line used for the treatment of common warts and verrucas (plantar warts) caused by human papillomavirus (HPV). It is available in two primary formulations: a cryotherapy version and a chemical peel version. The cryotherapy formulation utilizes a liquid gas mixture of dimethyl ether (75%) and propane (25%) to freeze the wart tissue down to the root, inducing a blister that eventually falls off within 10-14 days. The Wart & Verruca Removal Pen contains a trichloroacetic acid (TCA) gel, which acts as a chemical exfoliant to destroy virus-infected cells and promote the growth of healthy skin. Developed by Omega Teknika and distributed by Omega Pharma (a Perrigo company), Wartner is intended for use in adults and children aged four years and older.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wartner.